# Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)

> **NCT07486089** · PHASE1,PHASE2 · RECRUITING · sponsor: **Beijing Biotech** · enrollment: 60 (estimated)

## Conditions studied

- Breast Cancer (Locally Advanced or Metastatic)
- HER2-positive Breast Cancer
- Triple-Negative Breast Cancer (TNBC)

## Interventions

- **BIOLOGICAL:** Dual-target CAR-NK cells (EB-DT-CAR-NK)
- **DRUG:** Lymphodepleting chemotherapy
- **OTHER:** Supportive care

## Key facts

- **NCT ID:** NCT07486089
- **Lead sponsor:** Beijing Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-02
- **Primary completion:** 2027-02-14
- **Final completion:** 2028-03-17
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07486089

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07486089, "Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07486089. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*